Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK

被引：0
|
作者：
Alex Diamantopoulos
A. Finckh
T. Huizinga
D. K. Sungher
L. Sawyer
D. Neto
F. Dejonckheere
机构：
[1] Symmetron Limited,Rheumatology
[2] Kinetic Centre,Rheumatology
[3] University Hospitals of Geneva,undefined
[4] Leiden University Medical Center,undefined
[5] F. Hoffmann-La Roche,undefined
来源：
PharmacoEconomics | 2014年 / 32卷
关键词：
Palliative Care; Juvenile Idiopathic Arthritis; Tocilizumab; Visual Analogue Scale Pain; Health Assessment Questionnaire;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：775 / 787
页数：12
相关论文
共 50 条
  • [1] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Diamantopoulos, Alex
    Finckh, A.
    Huizinga, T.
    Sungher, D. K.
    Sawyer, L.
    Neto, D.
    Dejonckheere, F.
    [J]. PHARMACOECONOMICS, 2014, 32 (08) : 775 - 787
  • [2] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS, IN COLOMBIA
    Gamboa, O.
    Barbosa, D.
    Parada, L.
    Latorre, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A563 - A563
  • [3] COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Celik, H.
    Orfanos, P.
    [J]. VALUE IN HEALTH, 2018, 21 : S295 - S295
  • [4] COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB WITHOUT METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Celik, H.
    Orfanos, P.
    [J]. VALUE IN HEALTH, 2018, 21 : S297 - S297
  • [5] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB VERSUS INFLIXIMAB FOR THE PATIENTS WITH RHEUMATOID ARTHRITIS IN KAZAKHSTAN
    Bektur, C.
    Kayir, F.
    Nurgozhin, T.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A379 - A379
  • [6] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Desai, R. J.
    Rao, J.
    Biddle, A. K.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [7] THE COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA™) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A UK ANALYSIS
    Bansback, N.
    Brennan, A.
    Sengupta, N.
    Pang, F.
    [J]. RHEUMATOLOGY, 2004, 43 : 77 - 77
  • [8] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SUBCUTANEOUSCOMBOTHERAPY FIRST LINE FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS IN GREECE
    Athanasakis, K.
    Tarantilis, F.
    Skroumpelos, A.
    Kyriopoulos, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A538 - A538
  • [9] COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE MANAGEMENT OF INADEQUATELY RESPONDING RHEUMATOID ARTHRITIS PATIENTS
    Hansen, R. N.
    Best, J. H.
    Sullivan, S. D.
    Carlson, J. J.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A161 - A161
  • [10] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO
    Vargas-Valencia, J.
    Sotelo-Guzman, M.
    Mould-Quevedo, J. F.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A127 - A127
12345